HCG Curie Manavata Cancer Centre introduces Versius® Surgical Robotic System

Pioneering centre for cancer treatment, HCG Curie Manavata Cancer Centre, has commercially acquired the next-generation Versius® Surgical Robotic System.

CAMBRIDGE, UK. 18 October 2019. CMR Surgical Ltd, today announces that HCG Curie Manavata Cancer Centre in Nashik, India, has acquired Versius®, a next-generation Surgical Robotic System. This landmark introduction marks the first ever robotic system in the centre and the North Maharashtra region. A range of surgical procedures have already been completed using Versius at the state-of-the-art centre for oncology under the leadership of Dr Raj Nagarkar.

Dr Nagarkar Chief Surgical Oncologist and Managing Director of the Manavata Cancer Centre has pioneered oncology care in the region, specialising in surgical oncology. He founded the Manavata Cancer Center and has led an integrated approach to cancer care which focusses on delivering the right treatment and support to patients as early as possible. The introduction of Versius will bring robotic-assisted laparoscopic surgery and oncological care to the people of the North Maharashtra region, supporting the mission to make minimal access surgery available to all.

“The Manavata Cancer Centre has always strived to use cutting-edge cancer treatment. We are delighted to have acquired the Versius system as an innovative, cost effective system which will enable us to further our commitment of providing quality cancer care to the people of the North Maharashtra region, who until now have not had access to the benefits of robotic surgery.” said Dr Raj Nagarkar, Managing Director at HCG Curie Manavata Cancer Centre in Nashik, India.

“Manavata Cancer Centre are at the forefront of oncological care in not only the North Maharashtra region, but across India. Their acquisition of Versius is an important milestone in our mission to make minimal access surgery available to all. We are pleased to be working with a centre that provides, such innovative cancer care to be able to bring Versius to an area where surgical robotics was not previously accessible.” Said Mark Slack, Chief Medical Officer, CMR Surgical.

The introduction of Versius into the Manavata Cancer Centre marks the second commercial introduction of the surgical robotic system. Versius® as a next-generation surgical robotic system with its small form factor, versatility and portability has been designed to support surgeons to deliver the benefits of minimal access surgery to patients around the world.

This announcement follows the commercial launch of Versius at Galaxy Care Hospital in Pune, India with further commercial agreements in Europe expected to be announced imminently.
Notes to editors:

About the Manavata Cancer Centre, Maharashtra, India

The Manavata Cancer Centre was established in May 2007. The centre has transformed from a 35 bedded hospital, to a 275 bed, state-of-the-art, advanced oncology care centre in Maharashtra, India. Founded by Chief Surgical Oncologist & Managing Director, Dr Raj Nagarkar, MD., the centre joined hands with Healthcare Global Enterprises Pvt Ltd in 2010 to form the HCGMCC, an integrated cancer care centre focused on providing the right treatment and early intervention care to patients.

The Versius® Surgical Robotic System

Versius® resets expectations of robotic surgery by providing a versatile system that is portable, transportable and affordable. This is made possible because of its elegant form factor, modular design and individually cart-mounted arms. Versius® can move between operating rooms and even hospitals/clinics and gives the surgical team excellent access to the patient at all times.

Biomimicking the human arm, Versius® allows surgeons the freedom of port placement, but with the benefits of small fully-wristed instruments. With 3D HD vision, easy-to adopt instrument control and a choice of ergonomic working positions, the new open surgeon console has the potential to reduce stress and fatigue and extend the careers of surgeons.

About CMR Surgical Limited

CMR Surgical is a British private limited company developing the next-generation universal robotic system, Versius®, for minimal access surgery. The company received the European CE Mark in March 2019 for the Versius® Surgical Robotic System.

The vision behind CMR Surgical is to make minimal access surgery universally accessible and affordable, transforming the existing market for surgical robotics while also addressing the six million people who still undergo open surgery each year.

Global annual revenues for robot-assisted minimal access surgery are presently approximately $4 billion and are anticipated to reach $20 billion by 2025.

CMR Surgical, formed in 2014, has its headquarters in Cambridge, United Kingdom and is backed by an international shareholder base of specialist and generalist investors.

The Company achieved the registration of its Quality Management System to ISO 13485:2016 by Underwriters Laboratories LLC® (UL), and the status as a UL Registered Firm, in September 2015.

For further information, please visit www.cmrsurgical.com